Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Small Cell Lung Carcinoma 5Ovarian Neoplasms 3Lung Neoplasms 3Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Metastatic Bladder Urothelial Carcinoma 1HRD Cancer 1Colorectal Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Carboplatin 29Paclitaxel 22Taxes 16Bevacizumab 15Specimen Handling 10Immunoglobulin G 10Disulfides 10Magnetic Resonance Spectroscopy 9Gemcitabine 9Biopsy 9veliparib 8olaparib 8liposomal doxorubicin 7cediranib 6Doxorubicin 6Docetaxel 6Topotecan 5Chemotherapy, Adjuvant 4Oxaliplatin 3Immunohistochemistry 3Gene Expression Profiling 3temsirolimus 2reolysin 2oregovomab 2ipatasertib 2cabozantinib 2berzosertib 2belinostat 2atezolizumab 2aflibercept 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Fallopian Tube Neoplasms × berzosertib × Clear all
NCT02595892 2026-04-13

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
70 enrolled 23 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02627443 2026-04-13

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
35 enrolled 13 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡